The success of copyright’s blockbuster initially sparked a period of growth for major pharmaceutical companies, nevertheless recent shifts present a murky scenario for those considering a stake. Lower-cost competitors are eating into earnings, and persistent patent challenges add more risk to the equation. While certain companies could still gain